現代における心臓移植のパラダイムと将来の境界:最先端のフォーカスレビュー

Ameesh Isath¹, Milica Vukićević², Roxana Moayedifar³

¹Center for Advanced Heart Disease, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

Journal of cardiac failure

|September 1, 2025

まとめ

心臓移植の進歩は臓器の保存,ドナー基準の拡大, 精密免疫抑制などにより患者の成果が向上しています異種移植のようなイノベーションは臓器の不足に未来の解決策を提供してくれます

科学分野:

心臓病科
移植医学
免疫学

背景:

心臓移植は最終段階の心不全の重要な治療法です
臓器の入手や移植後の合併症など重要な課題が残っています

研究の目的:

心臓移植の現代的な進歩をレビューし,臨床的実践を転換する可能性を秘めています.
患者の成果を改善し,臓器不足に対処するイノベーションを強調する.

主な方法:

臓器の保存と輸送の最近の発展 (ex vivo perfusion, normothermic テクニック) のレビュー
心臓移植と左心房補助器官 (LVAD) 移植の意思決定に関する分析
拡張ドナー基準の検討 (循環死後のドナー,HCV陽性ドナー)
バイオマーカーを用いた精密免疫抑制戦略の概要
移植後の長期的ケアと遅い合併症について
異種移植の探索は未来の境界線として

主要な成果:

臓器保存の新技術は地理的な範囲を拡大し臓器提供者の心臓の使用を最適化します
個別化された生存効果評価は,移植とLVADの決定を導く.
DCDとHCV+のドナーによる臓器提供の拡大は臓器の可用性を高めます
精度の高い免疫抑制により拒絶が早期に検出され制御が改善されます
心臓移植の合併症や腎臓機能障害の管理に焦点を当てて下さい
異種移植は臓器の不足を克服する早期の希望を示しています

結論:

心臓移植は重要な臨床的科学的な進歩によって新しい時代に入っています
これらのイノベーションには臨床的適応能力と継続的な科学研究が必要です
長期的な合併症の管理と異種移植の探索

さらに関連する動画

08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

977

12:24

A Novel Microsurgical Model for Heterotopic, En Bloc Chest Wall, Thymus, and Heart Transplantation in Mice

Published on: January 23, 2016

9.4K

関連する概念動画

01:24

Tissue Transplantation

519

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

519

01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

01:17

Pathophysiology of Heart Failure

1.8K

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...

1.8K

01:27

Development of the Heart

1.2K

The development of the human heart, a crucial organ, commences from the mesoderm on the 18th or 19th day after fertilization. This process initiates in the cardiogenic area, a group of mesodermal cells at the embryo's head end, which evolves into elongated strands known as cardiogenic cords. These cords undergo a transformation to form hollow-centered endocardial tubes.
As the embryo undergoes lateral folding, these paired tubes approach each other, merging into a single primitive heart...

1.2K

01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.